In its full year results to June 30, the company, based at Innovation Way, Heslington, says the number of licenses for its Optimer binder technology have increased from 4 to 11.
These include royalty agreements with Neuro-Bio on diagnosing Alzheimers Disease and the University of Glasgow on using Optimers in vaccines.
Other negotiations are also underway with large pharmaceutical firms to increase such use, the company said.
RECOMMENDED READING:
Aptamer Group raises £2 million to fund investment drive
Aptamer also reported annual revenues of £1.2million, a 40 per cent increase on the £0.86million in the year to June 30 2024.
The adjusted EBITDA loss dropped from £2.8million to £2.4million over the same period.
Since June 30 this year, Apatamber also reported a successful completion of fundraising for £1.8 million (net) in July 2025, further strengthening the Group’s financial position to execute the growth strategy.
It also secured £675,000 in new contracts in Q1, delivering £1.0 million visibility for FY26, supported by a robust £3.4 million sales pipeline.
A development contract has also been secured with a top 3 pharma to develop Optimers for targeted radiopharmaceuticals.
There is also a new discovery and development agreement signed with Invizius to develop Optimer® therapeutics for the complement system for the treatment of inflammatory diseases.
The company has also launched a biomarker discovery service: introduced new biomarker discovery service targeting the substantial US$62.4 billion global biomarker discovery market, representing significant market opportunity expansion.
Arron Tolley, Chief Executive Officer of Aptamer Group, said: “This has been a year of significant strategic progress for Aptamer as we continued to expand the breadth and commercial reach of our Optimer® platform.
“With a 40% increase in revenue and a growing base of repeat business from leading pharmaceutical partners, our technology is gaining strong traction across life sciences and adjacent markets.”
Dr Tolley continued: “We have more than doubled Aptamer’s portfolio of licensable Optimer® assets from four to eleven, secured royalty-bearing agreements with Neuro-Bio and the University of Glasgow, and a global life science conglomerate.
“Additionally, we are in late-stage licensing negotiations for our enzyme-modulating assets, with two separate partners, which are expected to sign in the coming months.
“The expansion of our Unilever partnership, now including a second Optimer® development programme, underlines the commercial strength and versatility of our platform technology.”
He added: “Looking ahead, the successful £1.8 million fundraising completed after year-end provides the resources to accelerate our growth strategy, strengthen in-house manufacturing, and advance high-value Optimer® programmes.
“With an expanding pipeline, deepening commercial relationships, and a robust financial position, we are well-placed to deliver long-term value for our shareholders.“
